Jul 25, 2014 at 13:11 | Source: Moneycontrol.com
Bayer CropScience has reported a sales standalone turnover of Rs 1,200.70 crore and a net profit of Rs 108.50 crore for the quarter ended Jun '14
Jul 25, 2014 at 12:19 | Source: CNBC-TV18
Here are a few top buzzing stocks picked by CNBC-TV18's analysts in trade today - Wipro, M&M Financial, TVS Motors and a few stocks from the earnings aspect - PI Industries, Bayer Cropscience and Century Enka.
Jul 25, 2014 at 08:19 | Source: CNBC-TV18
Biocon | Bharti Infratel | SKS Microfinance | Ambuja Cements | Ranbaxy Labs | PNB | Ashok Leyland | Glenmark Pharma | Ambuja Cements | Mirc Electronics | PI Industries | Rajshree Sugars | Indiabulls Housing Finance | Birla Precision Technologies | TVS Motor | JSW Energy and Lanco Infratech are stocks, which are in the news today.
Jul 24, 2014 at 08:14 | Source: CNBC-TV18
Ranbaxy Labs | Wipro | TVS Motor | Cairn India | Cipla | Bank of India | Container Corporation | Geometric | Gujarat Alkalies | Alstom T&D India | McLeod Russel | L&T Finance Holdings | Panacea Biotec | Prestige Estates | Liberty Shoes | Patel Engineering | JSW Energy and ACC are stocks, which are in the news today.
Jul 19, 2014 at 16:08 | Source: Moneycontrol.com
Last week the Bombay High Court upheld the compulsory license granted to Indian pharma company Natco for the sale of a generic version of Bayer's anti-cancer drug Nexavar. Here's a look back at the first legal challenge against a compulsory license in India.
Jul 16, 2014 at 09:01 | Source: Moneycontrol.com
Natco is pleased to inform that the Bombay High Court upheld the compulsory license (CL) granted to the Company on Nexavar (sorafenib tosylate) of German drug Major Bayers patented kidney cancer drug.
Jul 15, 2014 at 18:02 | Source: CNBC-TV18
The Bombay High Court has refused to interfere in the order which was issued by the IPAB in March last year.
Jul 15, 2014 at 17:26 | Source: CNBC-TV18
Praful Borah of Nirmal Bang Equities does not see much of a financial impact but it does take off the entire uncertainty of the compulsory licensing.
Jul 08, 2014 at 12:24 | Source: Moneycontrol.com
Firstcall Research is bullish on Bayer CropScience and has recommended buy rating on the stock with a target of Rs 1985 in its July 4, 2014 research report.
Jun 27, 2014 at 22:25 | Source: CNBC-TV18
The key takeaway was that the company is looking at a unique approach of using single target for multiple indications, one drug that can treat multiple indications.